Please find a list of related firms in this jurisdiction to the right.
For more information on the firm profile, please contact Rebecca Synnott
Belmore Neidrauer is unique in that it is devoted entirely to IP litigation, with 90% of that being devoted to pharmaceutical litigation on behalf of innovators. "It is all very high-stakes, high-profile and high-end," confirms a peer. "It's a boutique but it's actually a bigger group than some of the IP departments of other firms." A client testifies, "The lean and efficient structure of this firm results in cost-effective work for us. Their deep insight and experience on pharma patent litigation is one of the factors for our long-lasting work relationship. They are prompt, realistic, proactive, and able to recommend odd and creative strategy based on less-known principles or regulations." The firm recently augmented its bench with the addition of former Norton Rose Fulbright partner Jason Markwell, a celebrated figure in the pharmaceutical community. Markwell acted as lead counsel for Gilead in a patent infringement action relating to the use of nucleoside analogs for the treatment of hepatitis. The key issues were sufficiency and utility. Gilead prevailed at trial, and the decision was upheld on appeal. He also acted as lead counsel for the Intellectual Property Institute of Canada as an intervenor on the case of AstraZeneca Canada v. Apotex, a patent infringement action relating to NEXIUM (esomeprazole). Markwell also was co-counsel for Bayer at trial and on appeal relating to Bayer's remedy flowing from alleged infringement on the part of Apotex. Ironically, former Belmore Neidrauer partner Mark Davis gravitated to Markwell's former firm; commenting on this, a peer ventures, "The switch made sense – Mark wasn't doing the hardcore pharma patent work, and he didn't want to. He was after a more varied practice. Jason, on the other hand, was chasing that work, so Belmore gives him the perfect platform for this."